Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05593640

Thromboxane A2 and Osteoarthritis

Sponsor: Centre Hospitalier Universitaire de Nice

View on ClinicalTrials.gov

Summary

TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i) to analyse the role of TXA2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue TXA2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of TXA2 with the development of osteoarthritis in a small human cohort. The proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat OA and associated metabolic disorders.

Official title: Throboxane Effect on Chondrocytes; Role in Osteoarthritis

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

OBSERVATIONAL

Enrollment

20

Start Date

2022-09-01

Completion Date

2027-06-25

Last Updated

2026-06-29

Healthy Volunteers

No

Conditions

Interventions

OTHER

biological samples

blood and synovial liquid will be sampled

Locations (1)

CHU de NICE

Nice, France